CoChat

Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery

Open access
Denis, Jérôme Alexandre, Patroni, Alexia, Guillerm, Erell, Pépin, Dominique, Benali-Furet, Naoual, Wechsler, Janine, Manceau, Gilles, Bernard, Maguy, Coulet, Florence, Larsen, Annette K., Karoui, Mehdi, Lacorte, Jean-Marc · 2016 · Molecular Oncology
Cited by 96

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR‐targeted antibodies cetuximab and panitumumab. Since it can be difficult to obtain appropriate tumor tissues for KRAS genotyping, alternative methods are required. Circulating tumor cells (CTCs) are believed to be representative of the tumor in real time. In this study we explored the capacity of a size‐based device for capturing CTCs coupled with a multiplex KRAS screening assay using droplet digital PCR (ddPCR). We showed that it is possible to detect a mutant ratio of 0.05% and less than one KRAS mutant cell per mL total blood with ddPCR compared to about 0.5% and 50–75 cells for TaqMeltPCR and HRM. Next, CTCs were isolated from the blood of 35 patients with CRC at various stage of the disease. KRAS genotyping was successful for 86% (30/35) of samples with a KRAS codon 12/13 mutant ratio of 57% (17/30). In contrast, only one patient was identified as KRAS mutant when size‐based isolation was combined with HRM or TaqMeltPCR. KRAS status was then determined for the 26 available formalin‐fixed paraffin‐embedded tumors using standard procedures. The concordance between the CTCs and the corresponding tumor tissues was 77% with a sensitivity of 83%. Taken together, the data presented here suggest that is feasible to detect KRAS mutations in CTCs from blood samples of CRC patients which are predictive for those found in the tumor. The minimal invasive nature of this procedure in combination with the high sensitivity of ddPCR might provide in the future an opportunity to monitor patients throughout the course of disease on multiple levels including early detection, prognosis, treatment and relapse as well as to obtain mechanistic insight with respect to tumor invasion and metastasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2016.05.009

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 96

Metadata

Authors
Denis, J. A., Patroni, A., Guillerm, E., Pépin, D., Benali-Furet, N., Wechsler, J., Manceau, G., Bernard, M., Coulet, F., Larsen, A. K., Karoui, M., & Lacorte, J.-M.
Venue
Molecular Oncology
Publisher
Wiley
Published
2016-06-07
Volume
10
Issue
8
Pages
1221-1231
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2413380883
Cited by
96
References
6
FWCI
4.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. https://app.cochat.ai/papers/10.1016/j.molonc.2016.05.009
The paper
Denis, J. A., Patroni, A., Guillerm, E., Pépin, D., Benali-Furet, N., Wechsler, J., Manceau, G., Bernard, M., Coulet, F., Larsen, A. K., Karoui, M., & Lacorte, J.-M. (2016). Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. Molecular Oncology. https://doi.org/10.1016/j.molonc.2016.05.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.